There is no established standard dose for this case; it is advisable to consult a professional.
Safety
Immunosuppressant; human use only under a physician or in a trial
Effect by goal · level of evidence
Longevity / cardiac function (canine, preliminary)
improves (preclinical/veterinary)Lowtrial (RCT in dogs) (A)
At low doses, rapamycin improved markers of cardiac function (ejection fraction, E/A ratio) in healthy middle-aged dogs, with no clinical adverse effects over 10 weeks. A geroprotection signal that fuels interest in longevity, but it is in DOGS and a prescription immunosuppressant: not extrapolable to healthy people.
⚠️ immunosuppressant; human use only under a physician or in a trial
Findings
Longevity / cardiac function (canine, preliminary) — improves (preclinical/veterinary) (Low, trial (RCT in dogs)). At low doses, rapamycin improved markers of cardiac function (ejection fraction, E/A ratio) in healthy middle-aged dogs, with no clinical adverse effects over 10 weeks. A geroprotection signal that fuels interest in longevity, but it is in DOGS and a prescription immunosuppressant: not extrapolable to healthy people. 28374166
Information, not medical advice. Prescription drugs require a doctor.
Information, not medical advice. Scientific evidence reflects the quality of the studies.